PJ, 8 November 2014, Vol 293, No 7835

Study measures impact of epilepsy drugs in utero

Women with epilepsy should be warned upon diagnosis that some treatments for the condition may cause adverse effects on the neurodevelopment of unborn babies.…

Patients’ fear of dementia is concealing its true prevalence

Stigma and fear associated with dementia is preventing early diagnosis and hampering researchers from obtaining a full picture of the disease, according to the International Longevity Centre UK. …

Smart drugs worth £200,000 seized in the UK

A haul of “smart drugs” with a street value of £200,000 has been seized in the UK. …

Parents warned to keep e-cigarettes out of reach as poisoning incidents increase

There has been a significant rise in the number of cases of children ingesting the liquid in e-cigarettes, prompting poison experts at Public Health England to warn parents to keep them out of reach.…

MPs question the value of the NHS Health Check

A report from an influential group of MPs suggests that the health check programme represented poor policy and may not achieve its intended aims.…

Identifying patients at risk of diabetes

With 11.5 million people at risk in the UK, it is essential to recognise the signs and symptoms of type 1 diabetes and type 2 diabetes.…

Almost all pharmacies rated satisfactory, with few considered to be good or excellent

More than 90% of the first pharmacies inspected by the General Pharmaceutical Council under its new inspection model were considered satisfactory, while only a handful were rated good and hardly any were judged to be excellent.…

Medicines regulator reviews chloramphenicol packaging after picking errors

Regulators are working with community pharmacy organisations to review the packaging of chloramphenicol eye and ear drops.…

Canagliflozin and dapagliflozin interactions in diabetes treatment

Find out which interactions are associated with the latest antidiabetic medicines.…

Green light for first treatment to target ovarian cancer with BRCA mutation

The European Medicines Agency has recommended that Lynparza (olaparib) be approved to combat a type of ovarian cancer for which there are limited treatment options.…